INDEMNIFICATION AGREEMENTIndemnification Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of [_____], 2022 , is entered into by and between Regentis Biomaterials Ltd., an Israeli company whose address is 12 Ha’ilan Street, Northern Industrial Zone, P.O. Box 260 Or-Akiva 306000, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page attached hereto (the “Indemnitee”).
AGREEMENTAgreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Agreement is entered into as of on December 5, 2022, effective as of March 31, 2022 (the “Commencement Date”), by and between Regentis Biomaterials Ltd., a company incorporated in the State of Israel whose address is 60 Medinat Hayehudim Street, Entrance C. Herzeliya, Israel (the “Company”), and Mr. Noam Band, ID no. [_________], of [______________]., Tel Aviv, Israel (the “Service Provider”).
SERIES B PREFERRED SHARE PURCHASE AGREEMENTSeries B Preferred Share Purchase Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS SERIES B PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is entered into on and as of this 2nd day of August, 2007, by and among (i) Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Company”); (ii) The Technological Incubator Founded by the Technion R&D Foundation Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 510340677, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Incubator”); (iii) Dr. Dror Seliktar of Bio-Medical Engineering Department, Technion, Technion City, Haifa 32000, Israel (“Seliktar”); (iv) Mr. Yehiel Tal of 6 Hamaish Street, Zichron Yaakov, Israel (“Tal”) (Seliktar and Tal each a “Founder” and collectively the “Founders”); and (iv) the investors listed on Schedule A to this Agreement (each, an “Investor” and
